We have recently found a novel oncogene, named cancer upregulated gene 2 (CUG2), which activates Ras and mitogen-activated protein kinases (MAPKs), including ERK, JNK and p38 MAPK. Because activation of these signaling pathways has previously been shown to enhance cancer cell susceptibility to oncolysis by certain viruses, we examined whether vesicular stomatitis virus (VSV) could function as a potential therapeutic agent by efficiently inducing cytolysis in cells transformed by CUG2. Unexpectedly, NIH3T3 cells stably expressing CUG2 (NIH-CUG2) were resistant to VSV because of the activation of signal transducers and activators of transcription 1 (STAT1). The result was supported by evidence showing that suppression of STAT1 with short interference RNA (siRNA) renders cells susceptible to VSV. Furthermore, 2 0 -5 0 oligoadenylate synthetase-like (OASL) 2 was the most affected by STAT1 expression level among anti-viral proteins and furthermore suppression of OASL2 mRNA level caused NIH-CUG2 cells to succumb to VSV as seen in NIH-CUG2 cells treated with STAT1 siRNA. In addition, Colon26L5 carcinoma cells stably expressing CUG2 (Colon26L5-CUG2) exhibited resistance to VSV, whereas Colon26L5 stably expressing a control vector yielded to VSV infection. Moreover, Colon26L5-CUG2 cells stably suppressing STAT1 succumbed to VSV infection, resulting in apoptosis. Taken together, we propose that VSV treatment combined with the selective regulation of genes such as STAT1 and OASL2 will improve therapeutic outcomes for CUG2-overexpressing tumors.
INTRODUCTION
To discover new genes that have a crucial role in common tumorigenesis regardless of tissue origin, we analyzed commonly upregulated unknown genes using 242 normal and 300 tumor samples originating from 11 different tissues with an Affymetrix gene chip system. An uncharacterized gene, later named cancer upregulated gene 2 (CUG2), was identified as a potential candidate that was commonly upregulated in various tumor tissues, including ovary, liver, lung, pancreas and colon. CUG2 was mapped to chromosome 6q22.32, extends about 8.5 kb in length with a 3-exon structure, encoding a 88-amino-acid polypeptide. 1 Further study has revealed that CUG2 protein is a novel component of centromeres required for proper kinetochore function during cell division. 2 Of interest, CUG2 has been shown to possess an oncogenic effect in a transplanted model using NIH3T3 cells expressing CUG2, behaving similarly to Ras. 1 Our previous study has shown that CUG2 activates Ras and mitogenactivated protein kinases (MAPKs) including p38 MAPK, which eventually facilitate reoviral replication and the death of virusinfected cancer cells. 3 Vesicular stomatitis virus (VSV), also known as a potential therapeutic anticancer agent, is a non-enveloped, negativestranded RNA virus and belongs to the Rhabdoviridae family. The RNA genome of VSV encodes five proteins, including nucleocapsid, polymerase proteins, surface glycoprotein and peripheral matrix protein. 4 VSV causes vesicular lesions in the mucous membranes of mouse and in the nasal tissues of horses, cattle and pigs. However, VSV does not induce significant symptoms in humans. Moreover, evidence of human exposure to VSV is generally uncommon in seroprevalence studies, 5 which is beneficial for the potential use of VSV as an oncolytic agent in human trials. Furthermore, VSV can replicate in malignant cells more efficiently than in normal cells as do other oncolytic viruses. [6] [7] [8] [9] Successful treatments with VSV have been reported in laboratory models of breast, lung, brain and colon cancers. [10] [11] [12] [13] However, VSV is very sensitive to the anti-viral activity of interferon (IFN) induction, and therefore improved strategies for the application of VSV have been sought for preferential replication in tumor cells and resistance to the anti-viral action of host cells. 10, 14 IFN-induced anti-viral proteins have been extensively studied. 2 0 -5 0 Oligoadenylate synthetase (OAS) stimulated by doublestranded RNA polymerizes ATP to 2 0 -and 5 0 -linked oligomers of adenosine and activates RNaseL by inhibiting initiation of protein synthesis or degrading RNA. 15 The OAS gene family contains four OAS members: OAS1, OAS2, OAS3 and OASL. 16 IFN-stimulated gene 15 (ISG15), a 15-kDa ubiquitin-like protein, has recently emerged as an important tool in the defense against viral infections. Like ubiquitin and other ubiquitin-like proteins, ISG15 is attached to target proteins through a C-terminal Gly-Gly motif, which is referred to as ISGylation and is implicated in anti-viral activity.
Guanylate-binding proteins (GBPs) are a family of large IFNinduced GTPases. 18 Although it is currently unclear how GBP functions in anti-viral activity, ectopic expression of GBP1 or GBP2 protects cells against VSV and encephalomyelitis virus infections. 19 IFN-inducible protein-10 (IP-10), a non-ELR CXC chemokine, is a chemoattractant for natural killer and T cells and is believed to be an important regulator of the T-helper type 1, interleukin-12-driven inflammatory responses as an inducer of cellular infiltration. 20 IFN-induced protein with tetratricopeptide repeat 3 (IFIT3) is significantly induced upon RNA virus infection. Recent study has shown that IFN-induced tetratricopeptide repeat protein IFIT3 potentiates anti-viral signaling by bridging mitochondrial anti-viral signaling complex and tumor necrosis factor receptorassociated factor family member-associated nuclear factor-kB activator-binding kinase 1. 21 Several lines of evidence have shown that Ras/Raf/MEK signaling reduces the threshold for VSV infection by attenuation of IFN signaling. 22, 23 Our observation that CUG2 upregulates Ras and MAPK activity 3 led us to predict that NIH3T3 cells transformed with CUG2 should become susceptible to VSV infection. In this study, we tested this hypothesis by asking whether VSV efficiently induces cytolysis in NIH3T3 cells transformed with CUG2. We unexpectedly found that CUG2 activates STAT1, leading to the upregulation of the anti-viral gene OASL2, which actually confers resistance to VSV infection. We also confirmed that activation of STAT1 mediated by CUG2 provides resistance to VSV in colon carcinoma cells. We herein suggest that VSV treatment combined with selective downregulation of genes such as STAT1 and OASL2 will enhance therapeutic efficiency for CUG2-overexpressing tumors.
MATERIALS AND METHODS

Cell cultures and virus amplification
NIH3T3 cells stably transfected with empty vector (NIH-Vec), oncogenic Ras(V12) expression plasmid (NIH-Ras) or CUG2 expression plasmid (NIH-CUG2) were used. In addition, Colon26-L5 cells stably transfected with the empty vector (Colon26L5-Vec) or the CUG2 expression plasmid (Colon26L5-CUG2), and Colon26L5-CUG2 cells stably transfected with a short hairpin RNA control vector (Colon26L5-CUG2-ShCon) or short hairpin RNA STAT1 vector (OriGene, Rockville, MD, USA) (Colon26L5-CUG2-ShSTAT1) were used. Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin, and streptomycin at 5% CO 2 and 37 1C. The stable cells were selected under puromycin (1 mg ml À 1 ) or zeocin (200 mg ml À 1 ) based on transfected vectors. VSV (Indiana strain) purchased from the ATCC (Manassas, VA, USA) was propagated in L929 cells and the viral titer was measured in plaque-forming units.
Reagents and antibodies
For immunoblotting, antibodies against phospho-STAT1, STAT1, phospho-STAT2, STAT2, caspase 8 and poly-ADP-ribose polymerase (PARP) were acquired from Cell Signaling Biotechnology (Danvers, MA, USA). Anti-Ras and b-actin antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-VSV glycoprotein (G) antibody was obtained from Abcam (Cambridge, MA, USA). Glutathione S-transferase (GST)-Raf-RBD fusion protein was obtained from Cytoskeleton (Denver, CO, USA). IFN-b was also purchased from R&D systems (Minneapolis, MN, USA).
Western blotting assays
Cells were harvested and lysed with lysis buffer (150 mM NaCl, 1% NP-40, 50 mM Tris-HCl (pH 7.5)) containing 0.1 mM Na 2 VO 3 , 1 mM NaF and protease inhibitors (Sigma, St Louis, MO, USA). For immunoblotting, proteins from whole-cell lysates were resolved by 10 or 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to nitrocellulose membranes. Primary antibodies were used at 1 : 1000 or 1 : 2000 dilutions, and secondary antibodies conjugated with horseradish peroxidase were used at 1 : 2000 dilutions in 5% non-fat dry milk. After the final washing, nitrocellulose membranes were exposed for an enhanced chemiluminescence assay using the LAS 4000 mini (Fuji, Tokyo, Japan).
Active ras capture assays
To capture GTP-bound Ras from cell lysates, a GST-Raf-RBD fusion protein was used as described elsewhere. 24 The cells were lysed with lysis buffer and glutathione-agarose beads (Clontech, Mountain View, CA, USA) were added to the supernatant, and the solutions were rocked on ice for 30 min to exclude nonspecific binding. After centrifugation, the supernatant was harvested, followed by the addition of GST-Raf-RBD (Cytoskeleton, Denver, CO, USA). The solution was rocked on ice for 1 h, followed by the addition of glutathione-agarose beads to capture active Ras, which binds to GSTRaf-RBD. After washing three times, the pellet was mixed with 40 ml of 2 Â SDS loading buffer. To detect the captured Ras, immunoblotting was performed with anti-Ras antibody (Santa Cruz Biotechnology).
Qualitative reverse transcription-polymerase chain reaction Total RNA was extracted from cells using the RNeasy mini kit (Qiagen, Valencia, CA, USA) in accordance with the manufacturer's instructions. In all, 2 mg of total RNA were converted to cDNA using Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA), and polymerase chain reaction (PCR) was performed using the specific primers designed by the Vector NTI software (Invitrogen). The cDNA products of each reaction were diluted, and PCR was run at the optimized cycle number. Glyceraldehyde 3-phosphate dehydrogenase mRNA was used as an internal standard. for melting curve analysis. Data analysis is based on relative quantitation method and DDCT value was used to determine the relative fold changes. 25 All the data were normalized with the housekeeping glyceraldehyde 3-phosphate dehydrogenase expression level.
Transfection with short interference RNA Cells were trypsinized and incubated overnight to achieve 60-70% confluence before short interference RNA (siRNA) transfection. STAT1 siRNA (Bioneer Corporation; 200 nM; sense, 5
, OASL2 siRNA (200 nM; commercially pre-made at Qiagen) or negative control siRNA (Bioneer Corporation) were mixed with Lipofectamine 2000 (Invitrogen). The cells were incubated with the transfection mixture for 6 h and then rinsed with Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. The cells were incubated for 48 h before harvest.
Microarrays
Total RNA was amplified and purified using the Ambion Illumina RNA amplification kit (Ambion, Austin, TX, USA) to yield biotinylated cRNA according to the manufacturer's instructions. Labeled cRNA samples (750 ng each) were hybridized to each mouse-8 expression bead array for 16-18 h at 58 1C, according to the manufacturer's instructions (Illumina, San Diego, CA, USA). Detection of array signal was carried out using Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the bead array manual. Arrays were scanned with an Illumina BeadArray Reader confocal scanner according to the manufacturer's instructions. The quality of hybridization and overall chip performance were monitored by visual inspection of both internal quality control and the raw scanned data. Raw data were extracted using the software provided by Illumina GenomeStudio v.2009.2 (Gene Expression Module v.1.5.4). Array data were filtered by detection P-value o0.05 (similar to signal to noise) in at least 50% of samples (we applied a filtering criterion for data analysis; higher signal value was required to obtain a detection P-value o0.05). Selected gene signal values were transformed as logarithms and normalized by quantiles. Comparative analysis between test and control samples was carried out.
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Statistical analysis
Data are presented as a means±s.d. The Student's t-test was used for statistical analysis, with P-value o0.05 defined as significance.
RESULTS
CUG2 expression confers resistance to VSV infection in NIH3T3 cells
After elevated levels of CUG2 with oncogenic activity were detected in various tumor tissues, such as ovary, liver, lung and colon, 1 we wondered whether oncolytic VSV treatment might effectively exert cytolysis in CUG2-expressing cells as a potential therapeutic anticancer strategy. To address this question, we used NIH3T3 cell lines expressing vector only (NIH-Vec), active Ras (NIHRas) or the CUG2 gene (NIH-CUG2) because we showed oncogenic activity of CUG2 in non-transformed NIH3T3 cells in our previous study.
1 NIH-Vec, NIH-Ras or NIH-CUG2 cells were infected with VSV (multiplicity of infection (MOI) ¼ 0.1) and harvested at 12, 24 and 48 h post-infection. We found that NIH-Ras cells were more susceptible to VSV infection compared with NIH-Vec cells ( Figures  1a and b) as described elsewhere. 22, 23 However, NIH-CUG2 cells that also showed higher levels and activity of Ras were unexpectedly resistant to VSV until 48 h and even at 72 h (Figures 1a and b: data not shown). To examine whether cell death observed in NIH-Vec and NIH-Ras cells are attributed to VSV replication, leading to apoptosis, VSV-G capsid protein and cleaved caspase 8 were detected using immunoblotting. Increased VSV-G-protein levels in NIH-Vec cells over the time course of VSV infection and saturation of VSV-G-protein levels in NIH-Ras cells at 24 h post-infection was observed (Figure 1c ). Of interest, we could not detect any VSV-G protein in NIH-CUG2 cells, suggesting that CUG2 inhibits VSV replication, contrary to our initiation prediction. Cleaved caspase 8, an indicator of apoptotic cell death, was detected at 48 h post-infection in NIH-Vec and NIHRas cells but not in NIH-CUG2 cells, which is consistent with the extent of VSV replication (Figure 1c ).
CUG2 induces aberrant STAT1 activation in NIH3T3 cells
As it has been reported that upregulation of Ras contributes to enhanced VSV replication due to suppression of IFN signaling, 23, 26 we examined Ras activity and levels in NIH-Vec, NIH-Ras and NIH-CUG2 cells. Ras protein was more abundant in NIH-CUG2 and NIHRas cells than in NIH-Vec cells (Figure 2a ). In addition, the level of active GTP-bound Ras proteins, as detected by GST-Raf-RBD fusion protein binding, was much higher in NIH-Ras cells and relatively higher in NIH-CUG2 cells than in NIH-Vec cells (Figure 2a) , indicating that activation of Ras is not the only factor that determines susceptibility to VSV infection. When we examined the phosphorylation of STAT1 and STAT2 (well known as signaling molecules of type I IFN), as possible explanations for the enhanced resistance to VSV infection in NIH-CUG2 cells, we found that NIH-CUG2 cells exhibit much higher levels of phosphorylated STAT1 than did NIH-Vec and NIH-Ras cells (Figure 2b) . However, phosphorylated STAT2 was not seen in any of the cell lines (Figure 2b) . We further compared the levels of phosphorylated STAT1 and STAT2 during type I IFN treatment and VSV infection in each cell type. During IFN-b treatment, NIH-Vec cells reached peak phosphorylation of STAT1 after 15 min and reduced the levels at 30 and 60 min post-treatment (Figure 2c ). NIH-Ras cells displayed no change in phosphorylated STAT1 levels during IFN treatment, indicating that these cells may not respond to IFN-b (Figure 2c) . NIH-CUG2 cells showed highly elevated phosphorylation of STAT1 (Figure 2c ). Of interest, phosphorylation of STAT2, which could not be seen in unstimulated conditions, was drastically enhanced in NIH-CUG2 cells, compared with that seen in NIH-Vec and NIH-Ras cells (Figure 2c ). In addition, phosphorylation of STAT1 was increased in NIH-Vec and NIH-Ras cells at 12 and 24 h following VSV infection, whereas elevated levels of phosphorylated STAT1 were observed in NIH-CUG2 cells during VSV infection (Figure 2d ). However, VSV infection did not induce STAT2 phosphorylation in any of these cells (Figure 2d ). These results suggest that CUG2 overexpression causes an aberrant response to type I IFN and VSV infection.
Suppression of STAT1 renders NIH-CUG2 cells susceptible to VSV infection To confirm that activation of STAT1 due to CUG2 overexpression causes resistance to VSV, we suppressed STAT1 expression with siRNA and then infected NIH-CUG2 cells with VSV. We first optimized STAT1 siRNA concentration to reduce STAT1 levels at (Figure 3b ; Po0.01). Furthermore, to investigate whether cell death in NIH-CUG2 cells after the combined treatment may be attributable to apoptosis evoked by the activation of caspase 8, we examined the level of cleaved caspase 8 cleavage in cell lysates following combined treatment. STAT1 siRNA treatment or VSV infection alone did not induce activation of caspase 8, whereas the combined treatment did (Figure 3c ). In addition, observation of the VSV capsid G protein at 60 h confirmed that apoptosis is directly related to VSV replication following combined treatment (Figure 3c ). Accordingly, we propose that STAT1 activation due to CUG introduction stimulates the formation of an anti-viral state, leading to resistance to VSV infection.
Upregulation of OASL2 transcripts mediated by CUG2 is dependent on STAT1 expression Based on our observation that STAT1 activation renders cells resistant to VSV, we investigated which downstream molecule of STAT1 is directly involved in its anti-viral activity. To answer this question, we compared transcript levels of anti-viral proteins in NIH-Vec and NIH-CUG2 cells using a microarray assay. We then found that transcripts of IP-10, GBP3, IFIT3 and OASL2 were upregulated more than fourfold in NIH-CUG2 cells compared with those in NIH-Vec cells (Figure 4a ). In particular, OASL2 transcripts were increased more than 10-fold in NIH-CUG2 cells compared with those in NIH-Vec cells (Figure 4a ). Furthermore, we confirmed that the elevated transcripts observed in microarray were actually detected as upregulated levels through RT-PCR assays (Figure 4b ). When the transcript levels of ISG-15, a well-known anti-viral protein, were also examined using RT-PCR, the level of ISG-15 was increased compared with that in NIH-Vec cells (Figure 4b ). To confirm how much transcripts of these anti-viral genes were upregulated, quantitative real-time RT-PCR was performed. As seen in the results of microarrays and conventional RT-PCR (Figures 4a and b) , OASL2 transcripts were upregulated more than 40-fold in NIH-CUG2 cells compared with those in NIH-Vec cells (Figure 4c ). Transcripts of the other genes, IFIT3, GBP, IP-10 and ISG-15, were increased more than 15-fold compared with those in NIH-Vec cells (Figure 4c ). Moreover, to identify which protein among the anti-viral proteins is most affected by STAT1 activation, we examined mRNA levels of the proteins through RT-PCR and real-time RT-PCR after STAT1 siRNA treatment. Transcripts of OASL2 were most significantly decreased among them after STAT1 siRNA treatment, whereas transcripts of IP-10 were least decreased (Figures 4d and e) . Based on these results, we suggest that upregulation of CUG2-mediated OASL2 transcripts is dependent on STAT1 activation.
Suppression of OASL2 renders NIH-CUG2 cells susceptible to VSV infection
To confirm that upregulation of OASL2 transcripts due to CUG2 confers resistance to VSV, we suppressed OASL2 expression using its siRNA and then infected NIH-CUG2 cells with VSV. We first optimized conditions for the suppression of OASL2 with its siRNA CUG2 confers resistance to VSV through STAT1 W Malilas et al resulted in a reduction in surviving cell numbers compared with OASL2 siRNA treatment or VSV infection alone (Po0.01) (Figure 5b) . Furthermore, to test whether cell death in NIH-CUG2 cells after the combined treatment is attributable to apoptosis, we examined the cleavage of PARP, which indicates activation of caspase 3 or 7, in cells subjected to combined treatment. The combined treatment did induce the cleavage of PARP during VSVinduced apoptosis (Figure 5c ). Furthermore, observation of the VSV capsid G protein at 48 h confirmed that apoptosis is directly related to VSV replication following combined treatment (Figure 5c ). Accordingly, we propose that STAT1 activation due to CUG2 introduction stimulates the formation of an anti-viral state, leading to resistance to VSV infection. CU2G2-mediated STAT1 activation confers resistance to VSV in Colon26-L5 carcinoma cells Furthermore, we wondered whether CUG2 expression induces activation of STAT1, and resistance to VSV in any other cells. We introduced CUG2 into colon carcinoma, Colon26-L5 cells. We confirmed that STAT1 activation was detected in Colon26-L5 cells stably expressing CUG2 (Colon26L5-CUG2) (in preparation). Colon26L5-CUG2 and its control, Colon26-L5 cells stably expressing a control vector (Colon26L5-Vec) were infected with VSV (MOI ¼ 0.1). Cell death was then monitored for 36 h. We found that Colon26L5-Vec cells were susceptible to VSV, whereas Colon26L5-CUG2 cells were resistant to VSV, as seen in NIH-Vec and NIH-CUG2 cells (Figure 6a) . We identified that cell death of Colon26L5-Vec cells was mediated by VSV propagation, leading to apoptosis (Figure 6c ). In addition, we next examined whether STAT1 suppression renders Colon26L5-CUG2 cells susceptible to VSV. To address this question, we introduced Colon26L5-CUG2 cells stably suppressing STAT1 (Colon26L5-CUG2-ShSTAT1), which was confirmed by immunoblotting (in preparation) and its control Colon26L5-CUG2-ShCon cells. Both of these cells were infected with VSV (MOI ¼ 0.1) and cell death was then examined for 36 h. We found that Colon26L5-CUG2-ShSTAT1 cells were susceptible to VSV, whereas Colon26L5-CUG2-ShCon cells were resistant to VSV (Figure 6b ). Moreover, we observed that cell death of Colon26L5-CUG2-ShSTAT1 cells was mediated by VSV replication and attributed to apoptosis (Figure 6c ). These results indicate that CUG2 expression induces activation of STAT1, which contributes resistance to VSV infection.
DISCUSSION
In general, it has been known that malignant cells are usually more susceptible to oncolytic VSV infection, whereas normal cells are relatively resistant to the viral infection. However, it is often difficult to understand precisely why some malignant cell populations remain resistant to viral oncolysis. Several studies have revealed that activation of the Ras/Raf/MEK signaling pathway attenuates IFN signaling-mediated anti-viral action, thereby preventing the normal inhibition of VSV RNA synthesis or reduction of STAT2 levels. 22, 23, 26 These lines of evidence would explain the preferential replication of VSV that is commonly observed in tumor cells rather than non-transformed cells. On the basis of these reports, we expected that NIH-CUG2 cells should be susceptible to VSV infection as we observed earlier that CUG2 upregulates the activity and levels of Ras and MAPKs including CUG2 confers resistance to VSV through STAT1 W Malilas et al ERK. However, we were surprised to find that NIH-CUG2-transformed cells are actually resistant to VSV, whereas NIH-Rastransformed cells are more susceptible to VSV compared with non-transformed NIH-Vec cells. We attribute this unexpected observation to CUG2-mediated STAT1 activation, leading to the upregulation of the OASL2 anti-viral protein. We furthermore demonstrated that CUG2 introduction activates STAT1 in relevant colon cells, leading to resistance to VSV ( Figure 6 ). Further investigation has also revealed that NIH-CUG2 cells also exhibit a constitutive STAT1 activation and more sensitive STAT2 activation during IFN-b treatment compared with NIH-Ras and NIH-Vec cells. The result indicates that NIH-CUG2 cells are still responsive to IFN signaling, which is contrary to other malignant cells with defective IFN signaling. In contrast, when we consider that NIH-CUG2 cells are susceptible to reovirus, 3 VSV seems to be more sensitive to IFN-related anti-viral signals when compared with reovirus. We also assume that not only Ras but also p38 MAPK activation contributes to enhance susceptibility to reoviral infection to NIH-CUG2 cells.
Mutants of VSV have been generated for use as cytolytic agents in various cancer cells. Among them, a mutant of matrix (M) protein of VSV displayed less efficient cytolysis of tumor cells but attenuated cytopathic effect on the tumor-bearing animal due to lower capacity to induce IFN production during the viral infection compared with wild-type VSV. 27 Recent study has shown that a mutant of glycoprotein in VSV exhibited efficient cytolysis and less cytopathogenicity compared with a mutant of the matrix protein in VSV. 28 Cytopathogenicity of VSV was considered as an important factor for the application of VSV to human patients as a cancer therapeutic drug. Further these studies have reported that normal cells are resistant to VSV infection due to the production of type I IFN, whereas tumor cells are sensitive to VSV infection due to less production of type I IFN. 27, 28 However, our situation is different from theirs. To overcome the enervated oncolytic action of VSV in cells responding to IFN signaling, one group has attempted to downregulate the IFN receptor in bladder cancer cells, which eventually enables VSV replication in the cells. 29 Similarly, in our experiments we have genetically downregulated the cellular anti-viral response by suppression of the protein levels using siRNA against STAT1 or OASL2. Although our suppression by siRNA treatment of STAT1 or OASL2 did not completely eliminate the protein, it appears that we nevertheless surpassed a threshold of viral restriction that was enough to permit VSV replication in NIH-CUG2 cells. As recent studies have reported that the existence of new cellular anti-viral signaling pathways such as Akt-EMSY(a transcriptional repressor)-ISG 30 and protein kinase C-a-histone deacetylase6-b-catenin-IRF3, 31 it will be interesting to examine whether blockage of these signaling pathways can render NIH-CUG2 cells susceptible to VSV.
Herein, we found that the activation of STAT-OASL2 axis signaling mediated by CUG2 exerts unexpected anti-viral activity. Thus, we were curious about the mechanism by which CUG2 might activate STAT1. Interestingly, a recent study has shown that CUG2 interacts with nucleophosmin (NPM1/B23) protein.
32 NPM1/ B23 protein has multiple functions, including cell growth, proliferation and resistance to stress. 33 We additionally found that NPM1/B23 protein is closely related to cancer development. 34 Based on these works, we speculate that CUG2, a component of kinetochores, has a role in the development of cancer at least in part through its interaction with NPM1/B23 protein. Cancerous cells mediated by the CUG2-NPM1/B23 signaling axis produce growth factors and cytokines, including epidermal growth factor and interleukin-6, which can then deliver signals to the secretory or neighboring cells in an autocrine or a paracrine manner. Moreover, it is known that not only IFN signaling but also growth factor signaling (such as epidermal growth factor) can activate 
STAT1
. 35 Taken together, we propose that the interaction of CUG2 with NPM1/B23 protein can activate epidermal growth factor release for cell proliferation, leading thereby to STAT1 activation. To answer more precisely how CUG2 overexpression might activate STAT1 through its interaction with NPM1/B23 protein, we are continuing our studies. We observed elevated transcripts levels of OASL2, ISG15, IP-10, IFIT3 and GBP3 in NIH-CUG2 cells and discovered by the analysis of a public database (www. genecards.org) that all of them harbor the binding sequence for STAT1 at their promoter sites, except for GBP3. This evidence supports our finding that the expression of OASL2 transcripts is dependent on the STAT1 expression level (Figures 4d and e) . Although it is known that OAS activated by double-stranded RNA stimulates RNase L, leading to degradation of double strandedviral RNA or decreased initiation of viral protein synthesis, we are interested in understanding the mechanism by which CUG2 suppresses viral propagation by inhibition of RNA replication or through blockade of viral protein synthesis. The molecular mechanism by which CUG2 confers resistance against VSV infection will provide new information that will be useful in developing drugs to treat cancer cells overexpressing oncogenic CUG2.
